Inclusion conjunctivitis

Active Ingredient: Doxycycline

Indication for Doxycycline

Population group: only children (1 year - 12 years old)

Inclusion conjunctivitis may be treated with oral doxycycline alone or in combination with topical agents.

For this indication, competent medicine agencies globally authorize below treatments:

2.2-4.4 mg/kg in 2 divided doses daily

Route of admnistration

Oral

Defined daily dose

2.2 - 4.4 mg per kg of body weight

Dosage regimen

From 2.2 To 4.4 mg per kg of body weight once every day

Loading dose

4.4 mg per kg of body weight

Maintenance dose

2.2 mg per kg of body weight

Detailed description

Children aged 8 years to less than 12 years

The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated.

In such circumstance, the doses for the treatment of acute infections are:

For children 45 kg or less – Initial dose: 4.4 mg/kg (in single or 2 divided doses) with maintenance dose: 2.2 mg/kg (in single or 2 divided doses). In the management of more severe infections, up to 4.4 mg/kg should be given throughout treatment.
For children over 45 kg – Dose administered for adults should be used.

Children aged from birth to less than 8 years

Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration.

Dosage considerations

Doxycycline tablets are administered by drinking a suspension of the tablets in a small amount of water. This should be done in the sitting or standing position and well before retiring at night to reduce the risk of oesophageal irritation and ulceration. If gastric irritation occurs, it is recommended that doxycycline be given with food or milk. Studies indicate that the absorption of doxycycline is not notably influenced by simultaneous ingestion of food or milk.

Active ingredient

Doxycycline
Doxycycline is primarily bacteriostatic and is believed to exert its antimicrobial effect by the inhibition of protein synthesis. Read more about Doxycycline

Related medicines

Summary of Product Characteristics (SPC) 2019: VIBRAMYCIN-D Dispersible Tablet

Structured Product Labeling (SPL) 2021: DOXY Powder for solution for injection

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.